Atrion Corp ATRI
We take great care to ensure that the data presented and summarized in this overview for ATRION CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ATRI
View all-
Black Rock Inc. New York, NY108KShares$00.0% of portfolio
-
Credit Suisse Ag Zurich, V83.93KShares$00.0% of portfolio
-
Pathstone Family Office, LLC Englewood, NJ1.03KShares$00.0% of portfolio
-
Benjamin F. Edwards & Company, Inc. St. Louis, MO160Shares$00.0% of portfolio
-
Wilen Investment Management Corp.157Shares$00.09% of portfolio
-
Brewin Dolphin LTD London, X036Shares$00.0% of portfolio
-
Four Thought Financial, LLC Venice, FL30Shares$00.0% of portfolio
-
Wipfli Financial Advisors Llc,9Shares$00.0% of portfolio
-
Huntington National Bank Columbus, OH1Shares$00.0% of portfolio
Latest Institutional Activity in ATRI
Top Purchases
Top Sells
About ATRI
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Canada, Europe, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise Myocardial Protection System that delivers fluids and medications and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measure the activated clotting time of blood; and products for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.
Insider Transactions at ATRI
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 21
2024
|
John P Stupp Jr Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
143,932
-100.0%
|
$66,208,720
$460.0 P/Share
|
Aug 21
2024
|
John P Stupp Jr Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,394
-100.0%
|
$2,941,240
$460.0 P/Share
|
Aug 21
2024
|
Ronald Nicholas Spaulding Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,678
-100.0%
|
$1,231,880
$460.0 P/Share
|
Aug 21
2024
|
Preston G Athey Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,368
-100.0%
|
$629,280
$460.0 P/Share
|
Aug 21
2024
|
Jeannette Bankes Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
186
-100.0%
|
$85,560
$460.0 P/Share
|
Aug 21
2024
|
Emile A Battat Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
150,616
-100.0%
|
$69,283,360
$460.0 P/Share
|
Aug 21
2024
|
David A Battat President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
40,676
-100.0%
|
$18,710,960
$460.0 P/Share
|
Aug 21
2024
|
David A Battat President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,276
+3.04%
|
-
|
Aug 21
2024
|
David A Battat President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
55,500
-100.0%
|
$25,530,000
$460.0 P/Share
|
Aug 21
2024
|
Cindy Ferguson Officer / CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
118
-100.0%
|
$54,280
$460.0 P/Share
|
Jul 01
2024
|
Emile A Battat Director |
BUY
Sale (or disposition) back to the issuer
|
Direct |
310
+0.21%
|
$140,120
$452.43 P/Share
|
Jul 01
2024
|
Emile A Battat Director |
BUY
Exercise of conversion of derivative security
|
Direct |
310
+0.21%
|
-
|
Jul 01
2024
|
David A Battat President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
310
-0.79%
|
$140,120
$452.43 P/Share
|
Jul 01
2024
|
David A Battat President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
310
+0.78%
|
-
|
Mar 08
2024
|
Cindy Ferguson Officer / CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
45
-27.61%
|
$19,800
$440.8 P/Share
|
Mar 08
2024
|
Cindy Ferguson Officer / CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
163
+50.0%
|
-
|
Dec 01
2023
|
Preston G Athey Director |
BUY
Open market or private purchase
|
Direct |
300
+17.99%
|
$95,700
$319.68 P/Share
|
Nov 16
2023
|
David A Battat President & CEO |
BUY
Open market or private purchase
|
Direct |
300
+0.76%
|
$90,000
$300.0 P/Share
|
Sep 20
2023
|
Jeannette Bankes Director |
BUY
Grant, award, or other acquisition
|
Direct |
186
+50.0%
|
$82,584
$444.03 P/Share
|
Aug 15
2023
|
Preston G Athey Director |
BUY
Grant, award, or other acquisition
|
Direct |
200
+15.77%
|
$104,600
$523.35 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.28K shares |
---|---|
Exercise of conversion of derivative security | 783 shares |
Sale (or disposition) back to the issuer | 310 shares |
Open market or private purchase | 300 shares |
Sale (or disposition) back to the issuer | 402K shares |
---|---|
Payment of exercise price or tax liability | 45 shares |